CRIS : Summary for Curis, Inc. - Yahoo Finance

U.S. Markets open in 1 hr 57 mins

Curis, Inc. (CRIS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.96+0.10 (+3.50%)
At close: 4:00PM EDT
People also watch
ARQLCERSAGENCYTRARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.86
Open2.89
Bid2.50 x 1000
Ask3.99 x 100
Day's Range2.89 - 3.00
52 Week Range1.42 - 3.72
Volume1,069,285
Avg. Volume534,762
Market Cap419.99M
Beta2.44
PE Ratio (TTM)-6.51
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Curis, Inc. :CRIS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube7 days ago

    Curis, Inc. :CRIS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Curis, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Curis, Inc. – Exelixis, Inc., Infinity Pharmaceuticals, Inc., Emergent BioSolutions Inc., Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Pfizer Inc. and Celgene Corporation (EXEL-US, INFI-US, EBS-US, BMY-US, ... Read more (Read more...)

  • GlobeNewswire11 days ago

    Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference

    LEXINGTON, Mass., March 16, 2017-- March 16, 2017- Curis, Inc., a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, ...

  • Curis, Inc. :CRIS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
    Capital Cube13 days ago

    Curis, Inc. :CRIS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017

    Categories: Yahoo Finance Get free summary analysis Curis, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Curis, Inc. – Exelixis, Inc., Emergent BioSolutions Inc., Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., Pfizer Inc. and Celgene Corporation (EXEL-US, EBS-US, BMY-US, SPPI-US, PFE-US and CELG-US) that have also ... Read more (Read more...)